Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis

Katrin Patrij, Marcel Reiser, Luise Wätzel, Hendrik Pels, Annika Kowoll, Ulrich Herrlinger, Andreas Engert, Michael Linnebank, Gabriele Schackert, Marlies Vogt-Schaden, Gerlinde Egerer, Monika Lamprecht, Tracy T. Batchelor, Uwe Schlegel, Ingo G. H. Schmidt-Wolf & International Primary CNS Lymphoma Collaborative Group (IPCG)
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD...